JP6611736B2 - 疼痛に対する多様な活性を有する1−オキサ−4,9−ジアザスピロウンデカン化合物のアルキル誘導体 - Google Patents

疼痛に対する多様な活性を有する1−オキサ−4,9−ジアザスピロウンデカン化合物のアルキル誘導体 Download PDF

Info

Publication number
JP6611736B2
JP6611736B2 JP2016570805A JP2016570805A JP6611736B2 JP 6611736 B2 JP6611736 B2 JP 6611736B2 JP 2016570805 A JP2016570805 A JP 2016570805A JP 2016570805 A JP2016570805 A JP 2016570805A JP 6611736 B2 JP6611736 B2 JP 6611736B2
Authority
JP
Japan
Prior art keywords
unsubstituted
oxa
ethyl
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016570805A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017516818A (ja
Inventor
ヴィルジリ−ベルナド,マリナ
アロンソ−サルマ,モニカ
アレグレット−モリナ,カルロス
アルマンサ−ロサレス,カルメン
ロペス,モニカ ガルシア
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Esteve Pharmaceuticals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Pharmaceuticals SA filed Critical Esteve Pharmaceuticals SA
Publication of JP2017516818A publication Critical patent/JP2017516818A/ja
Application granted granted Critical
Publication of JP6611736B2 publication Critical patent/JP6611736B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2016570805A 2014-06-02 2015-06-02 疼痛に対する多様な活性を有する1−オキサ−4,9−ジアザスピロウンデカン化合物のアルキル誘導体 Expired - Fee Related JP6611736B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382209 2014-06-02
EP14382209.6 2014-06-02
PCT/EP2015/001115 WO2015185209A1 (en) 2014-06-02 2015-06-02 Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain

Publications (2)

Publication Number Publication Date
JP2017516818A JP2017516818A (ja) 2017-06-22
JP6611736B2 true JP6611736B2 (ja) 2019-11-27

Family

ID=50972618

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016570805A Expired - Fee Related JP6611736B2 (ja) 2014-06-02 2015-06-02 疼痛に対する多様な活性を有する1−オキサ−4,9−ジアザスピロウンデカン化合物のアルキル誘導体

Country Status (21)

Country Link
US (2) US10246465B2 (cg-RX-API-DMAC7.html)
EP (1) EP3149006B1 (cg-RX-API-DMAC7.html)
JP (1) JP6611736B2 (cg-RX-API-DMAC7.html)
KR (1) KR102468874B1 (cg-RX-API-DMAC7.html)
CN (1) CN106414457B (cg-RX-API-DMAC7.html)
AR (1) AR100715A1 (cg-RX-API-DMAC7.html)
AU (1) AU2015271248B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016027825B1 (cg-RX-API-DMAC7.html)
CA (1) CA2949573C (cg-RX-API-DMAC7.html)
IL (1) IL249016B (cg-RX-API-DMAC7.html)
MX (1) MX2016015760A (cg-RX-API-DMAC7.html)
MY (1) MY177365A (cg-RX-API-DMAC7.html)
NZ (1) NZ726476A (cg-RX-API-DMAC7.html)
PH (1) PH12016502307B1 (cg-RX-API-DMAC7.html)
RU (1) RU2720406C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201810660QA (cg-RX-API-DMAC7.html)
TN (1) TN2016000509A1 (cg-RX-API-DMAC7.html)
TW (1) TWI685497B (cg-RX-API-DMAC7.html)
UA (1) UA124049C2 (cg-RX-API-DMAC7.html)
WO (1) WO2015185209A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201608079B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201615643A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之1-氧雜-4,9-二氮雜螺十一烷化合物之烷基與芳基衍生物
AR106444A1 (es) * 2015-10-23 2018-01-17 Esteve Labor Dr Compuestos oxaazaespíricos con actividad contra el dolor
RS59956B1 (sr) 2015-10-23 2020-03-31 Esteve Pharmaceuticals Sa Oksa-diazaspiro jedinjenja koja imaju aktivnost protiv bola
TN2018000122A1 (en) * 2015-11-16 2019-10-04 Esteve Labor Dr Oxadiazaspiro compounds for the treatment of drug abuse and addiction
US10807970B2 (en) * 2016-05-20 2020-10-20 Esteve Pharmaceuticals, S.A. Tetrahydropyran and thiopyran derivatives having multimodal activity against pain
FI3697795T3 (fi) * 2017-10-17 2024-02-23 Acondicionamiento Tarrasense (R)-9-(2,5-difluorifenetyyli)-4-etyyli-2-metyyli-1-oksa-4,9-diatsaspiro[5.5]undekan-3-onin suoloja
WO2019158634A1 (en) 2018-02-16 2019-08-22 Esteve Pharmaceuticals, S.A. Deuterated derivatives of 9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
WO2019180188A1 (en) * 2018-03-23 2019-09-26 Esteve Pharmaceuticals, S.A. Aminopropoxyphenyl and benzyl 1-oxa-4,9-diazaspiroundecane derivatives having multimodal activity against pain
WO2020157026A1 (en) * 2019-01-28 2020-08-06 Esteve Pharmaceuticals, S.A. Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
WO2021018824A1 (en) 2019-07-31 2021-02-04 Esteve Pharmaceuticals, S.A. Use of (r)-9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one for the treatment of nociceptive pain, neuropathic pain, osteoarthritis pain and cancer pain, while having reduced side effects compared to opioids
WO2024105225A1 (en) 2022-11-18 2024-05-23 Universitat De Barcelona Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2133610B1 (cg-RX-API-DMAC7.html) * 1971-04-15 1975-10-31 Sumitomo Chemical Co
US4332804A (en) * 1981-03-23 1982-06-01 Syntex (U.S.A.) Inc. 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones
US4353900A (en) * 1981-10-19 1982-10-12 Syntex (U.S.A.) Inc. 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones
US6114541A (en) 1997-03-10 2000-09-05 Hoffmann-La Roche Inc. Method for the preparation of α-Bromo-Lactam derivatives
RU2477136C2 (ru) * 2004-03-03 2013-03-10 Вайтал Хэлф Сайнсис Пти Лтд Алкалоидные составы
DE102005030051A1 (de) 2005-06-27 2006-12-28 Grünenthal GmbH Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
DE102005030061A1 (de) 2005-06-27 2006-12-28 Behr Gmbh & Co. Kg Klimagerät
PT1961744E (pt) 2005-11-18 2013-05-15 Ono Pharmaceutical Co Composto que contém um grupo básico e sua utilização
CN101622241B (zh) 2007-03-01 2013-05-22 田边三菱制药株式会社 苯并咪唑化合物及其医药用途
EP1982714A1 (en) 2007-04-16 2008-10-22 Laboratorios del Dr. Esteve S.A. Pyrano-pyrazole-amines
EP2020414A1 (en) 2007-06-20 2009-02-04 Laboratorios del Dr. Esteve S.A. spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis
EP2197876A1 (en) 2007-08-29 2010-06-23 Glaxosmithkline LLC Thiazole and oxazole kinase inhibitors
CN102083839B (zh) 2008-02-06 2014-03-26 阿斯利康(瑞典)有限公司 化合物
US8828996B2 (en) * 2011-03-14 2014-09-09 Vertex Pharmaceuticals Incorporated Morpholine-spirocyclic piperidine amides as modulators of ion channels
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
TW201615643A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性之1-氧雜-4,9-二氮雜螺十一烷化合物之烷基與芳基衍生物
TW201615642A (zh) 2014-06-02 2016-05-01 伊史帝夫博士實驗室股份有限公司 具有多重模式抗疼痛活性的1-氧雜-4,9-二氮雜螺十一烷化合物之醯胺衍生物

Also Published As

Publication number Publication date
MX2016015760A (es) 2017-04-10
CN106414457A (zh) 2017-02-15
PH12016502307B1 (en) 2020-02-28
BR112016027825A2 (cg-RX-API-DMAC7.html) 2017-08-22
RU2016150518A3 (cg-RX-API-DMAC7.html) 2019-01-21
IL249016A0 (en) 2017-01-31
WO2015185209A1 (en) 2015-12-10
EP3149006B1 (en) 2020-09-09
UA124049C2 (uk) 2021-07-14
US10246465B2 (en) 2019-04-02
CA2949573C (en) 2023-07-18
AR100715A1 (es) 2016-10-26
KR20170012444A (ko) 2017-02-02
JP2017516818A (ja) 2017-06-22
SG10201810660QA (en) 2018-12-28
RU2720406C2 (ru) 2020-04-29
US20170313723A1 (en) 2017-11-02
KR102468874B1 (ko) 2022-11-17
TN2016000509A1 (en) 2018-04-04
ZA201608079B (en) 2017-09-27
AU2015271248A1 (en) 2016-12-15
TWI685497B (zh) 2020-02-21
IL249016B (en) 2020-05-31
NZ726476A (en) 2023-07-28
MY177365A (en) 2020-09-14
EP3149006A1 (en) 2017-04-05
CN106414457B (zh) 2020-04-17
AU2015271248B2 (en) 2019-10-31
RU2016150518A (ru) 2018-07-16
US20190177337A1 (en) 2019-06-13
PH12016502307A1 (en) 2017-02-13
SG11201609632UA (en) 2016-12-29
BR112016027825B1 (pt) 2023-03-28
CA2949573A1 (en) 2015-12-10
TW201617352A (zh) 2016-05-16

Similar Documents

Publication Publication Date Title
KR102468874B1 (ko) 통증에 대하여 다중모드 활성을 갖는 1-옥사-4,9-디아자스피로 운데칸 화합물의 알킬 유도체
JP6535687B2 (ja) 疼痛に対する多様な活性を有する1−オキサ−4,9−ジアザスピロウンデカン化合物のアルキルおよびアリール誘導体
JP6516773B2 (ja) 疼痛に対する多様な活性を有する1−オキサ−4,9−ジアザスピロウンデカン化合物のアミド誘導体
WO2017178515A1 (en) Piperidinylalkylamide derivatives having multimodal activity against pain
JP2017535545A (ja) 疼痛に対する多様な活性を有するスピロ−イソキノリン−1,4’−ピペリジン化合物
US10022359B2 (en) 1,9-diazaspiro undecane compounds having multimodal activity against pain
US20190031615A1 (en) 3-ethyl-3-phenylazepane derivatives having multimodal activity against pain
US10071968B2 (en) Methyl-1H-pyrazole alkylamine compounds having multimodal activity against pain
US10189828B2 (en) 1-methylpyrazole-piperazine compounds having multimodal activity against pain
EP3328847B1 (en) N-(2-(3-(benzyl(methyl)amino)pyrrolidin-1-yl)ethyl)-n-phenyl)propionamide derivatives and related compounds as dual sigma 1 and mu opioid receptor ligands for the treatment of pain
US10508114B2 (en) Spiro-isoquinoline-4,4′-piperidine compounds having multimodal activity against pain
WO2020157026A1 (en) Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
CN111225901A (zh) 用于治疗疼痛和与疼痛相关的病症的丙胺衍生物
WO2018153545A1 (en) Piperidine methanone derivatives having multimodal activity against pain
US20200010457A1 (en) Tetrahydropyran and tetrahydrothiopyran amide derivatives having multimodal activity against pain
WO2018153546A1 (en) Tetrahydropyran and tetrahydrothiopyran methanone derivatives having multimodal activity against pain

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180507

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20181129

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190625

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190918

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20191015

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20191029

R150 Certificate of patent or registration of utility model

Ref document number: 6611736

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees